TY - JOUR
T1 - Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations
AU - Feurstein, Simone
AU - Adegunsoye, Ayodeji
AU - Mojsilovic, Danijela
AU - Vij, Rekha
AU - West DePersia, Allison H.
AU - Rajagopal, Padma Sheila
AU - Osman, Afaf
AU - Collins, Robert H.
AU - Kim, Raymond H.
AU - Gore, Steven D.
AU - Greenberg, Peter
AU - Godley, Lucy A.
AU - Li, Zejuan
AU - Del Gaudio, Daniela
AU - Subramanian, Hari Prasanna
AU - Das, Soma
AU - Walsh, Tom
AU - Gulsuner, Suleyman
AU - Segal, Jeremy P.
AU - Husain, Aliya N.
AU - Gurbuxani, Sandeep
AU - King, Mary Claire
AU - Strek, Mary E.
AU - Churpek, Jane E.
N1 - Publisher Copyright:
© 2020 American Society of Hematology. All rights reserved.
PY - 2020/10
Y1 - 2020/10
N2 - Telomere biology disorders (TBDs) present heterogeneously, ranging from infantile bone marrow failure associated with very short telomeres to adult-onset interstitial lung disease (ILD) with normal telomere length. Yield of genetic testing and phenotypic spectra for TBDs caused by the expanding list of telomere genes in adults remain understudied. Thus, we screened adults aged $18 years with a personal and/or family history clustering hematologic disorders and/or ILD enrolled on The University of Chicago Inherited Hematologic Disorders Registry for causative variants in 13 TBD genes. Sixteen (10%) of 153 probands carried causative variants distributed among TERT (n 5 6), TERC (n 5 4), PARN (n 5 5), or RTEL1 (n 5 1), of which 19% were copy number variants. The highest yield (9 of 22 [41%]) was in families with mixed hematologic and ILD presentations, suggesting that ILD in hematology populations and hematologic abnormalities in ILD populations warrant TBD genetic testing. Four (3%) of 117 familial hematologic disorder families without ILD carried TBD variants, making TBD second to only DDX41 in frequency for genetic diagnoses in this population. Phenotypes of 17 carriers with heterozygous PARN variants included 4 (24%) with hematologic abnormalities, 67% with lymphocyte telomere lengths measured by flow cytometry and fluorescence in situ hybridization at or above the 10th percentile, and a high penetrance for ILD. Alternative etiologies for cytopenias and/or ILD such as autoimmune features were noted in multiple TBD families, emphasizing the need to maintain clinical suspicion for a TBD despite the presence of alternative explanations. 10.1182/bloodadvances.2020001721.
AB - Telomere biology disorders (TBDs) present heterogeneously, ranging from infantile bone marrow failure associated with very short telomeres to adult-onset interstitial lung disease (ILD) with normal telomere length. Yield of genetic testing and phenotypic spectra for TBDs caused by the expanding list of telomere genes in adults remain understudied. Thus, we screened adults aged $18 years with a personal and/or family history clustering hematologic disorders and/or ILD enrolled on The University of Chicago Inherited Hematologic Disorders Registry for causative variants in 13 TBD genes. Sixteen (10%) of 153 probands carried causative variants distributed among TERT (n 5 6), TERC (n 5 4), PARN (n 5 5), or RTEL1 (n 5 1), of which 19% were copy number variants. The highest yield (9 of 22 [41%]) was in families with mixed hematologic and ILD presentations, suggesting that ILD in hematology populations and hematologic abnormalities in ILD populations warrant TBD genetic testing. Four (3%) of 117 familial hematologic disorder families without ILD carried TBD variants, making TBD second to only DDX41 in frequency for genetic diagnoses in this population. Phenotypes of 17 carriers with heterozygous PARN variants included 4 (24%) with hematologic abnormalities, 67% with lymphocyte telomere lengths measured by flow cytometry and fluorescence in situ hybridization at or above the 10th percentile, and a high penetrance for ILD. Alternative etiologies for cytopenias and/or ILD such as autoimmune features were noted in multiple TBD families, emphasizing the need to maintain clinical suspicion for a TBD despite the presence of alternative explanations. 10.1182/bloodadvances.2020001721.
UR - http://www.scopus.com/inward/record.url?scp=85095771354&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095771354&partnerID=8YFLogxK
U2 - 10.1182/BLOODADVANCES.2020001721
DO - 10.1182/BLOODADVANCES.2020001721
M3 - Article
C2 - 33035329
AN - SCOPUS:85095771354
SN - 2473-9529
VL - 4
SP - 4883
EP - 4886
JO - Blood Advances
JF - Blood Advances
IS - 19
ER -